Skip to main content
Premium Trial:

Request an Annual Quote

Techne Acquires 39 Percent Stake in Discovery Genomics

NEW YORK, Aug. 3 – Biotech holding company Techne has acquired a 39 percent interest in Discovery Genomics and rights to develop antibodies and immunoassays for proteins targets that Discovery Genomics discovers, Techne said on Friday.

The agreement allows Techne exclusively to sell products based on Discovery Genomics’ discoveries in the research market royalty-free. Techne may also opt to sell similar products in the diagnostic market with obligations to pay royalties to Discovery Genomics.

Techne said in a statement that the company would classify a portion of Discovery Genomics’ losses as a Techne research expense. Techne predicted those losses would not exceed $1 million during the first year, and $2 million during the second and third year.

Techne also obtained warrants to acquire additional equity in Discovery Genomics.

Financial details of the deal were not disclosed. 

Minneapolis, Minn.-based Techne controls Research and Diagnostic Systems and R&D Systems, headquartred in Abingdon, UK. Both companies manufacture and distribute research and diagnostic biotechnology products. 

Discovery Genomics, also based in Minneapolis, has licensed gene knock-down and transposon technology from the University of Minnesota for applications in functional genomics and drug discovery. 

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.